Five Phase 3 Trials to Watch at ESMO 2026 Positive toplines are in for INTerpath-001, VOLGA, DeLLphi-305, KRAScendo 1 and SAFFRON. Madrid must now show the effect sizes: HRs, absolute survival gains and toxicity. That is where practice changing claims will be tested. #ESMO26 #Oncology